TY - JOUR
T1 - How to Best Protect People With Diabetes From the Impact of SARS-CoV-2
T2 - Report of the International COVID-19 and Diabetes Summit
AU - Zhang, Jennifer Y.
AU - Shang, Trisha
AU - Ahn, David
AU - Chen, Kong
AU - Coté, Gerard
AU - Espinoza, Juan
AU - Mendez, Carlos E.
AU - Spanakis, Elias K.
AU - Thompson, Bithika
AU - Wallia, Amisha
AU - Wisk, Lauren E.
AU - Kerr, David
AU - Klonoff, David C.
N1 - Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jennifer Y. Zhang, Trisha Shang, Kong Chen, Bithika Thompson, and Lauren E. Wisk have nothing of interest to disclose. David Ahn has served as a consultant, advisory board member, or speaker for Ascensia, Eli Lilly, and Senseonics. Gerard Coté is the founder of BioTex Inc. and Base Pair Technologies, Inc. Juan Espinoza’s efforts were supported by the Food and Drug Administration under award number P50FD006425 for The West Coast Consortium for Technology & Innovation in Pediatrics. The funding source had no involvement in the development of this manuscript or in the decision to submit the paper for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the FDA. Elias K. Spanakis was partially supported by the Veterans Affairs (VA) MERIT award (#1I01CX001825) from the United States Department of Veterans Affairs Clinical Sciences Research and Development Service. EKS has received unrestricted research support from Dexcom (to Baltimore VA Medical Center and to University of Maryland) for the conduction of clinical trials. Amisha Wallia has received research funding from Novo Nordisk and research support from Eli Lilly and the UnitedHealth Group. Carlos E. Mendez serves on the Medical Advisory Board for Monarch Medical Technologies (EndoTool). David Kerr is a consultant for Sanofi, Novo Nordisk, and Glooko, and has received research support from Abbott Diabetes Care and Eli Lilly. David C. Klonoff is a consultant for Dexcom, EOFlow, Fractyl, Lifecare, Novo Nordisk, Roche Diagnostics, Samsung, and Thirdwayv.
Funding Information:
We acknowledge grant support for this meeting and report from Glytec Systems and UBS. For contributing key points to this report and reviewing the manuscript, we would like to thank: Amesh Adalja, MD, Shivani Agarwal, MD, MPH, Joseph Aloi, MD, Zoltan Antal, MD, Jacob M. Appel, MD, JD, MPH, Nicholas Argento, MD, FACE, Eirik Årsand, PhD, Christina M. Astley, MD, ScD, Marissa Baker, PhD, Lynn Barr, MPH, Kristin Bennett, PhD, James Bernasko, MD, Frank Best, MD, Evan Martin Bloch, MD, MS, Anders Carlson, MD, Mercedes Carnethon, PhD, William Cefalu, MD, Daniel Cherñavvsky, MD, Curtiss B. Cook, MD, David A. Drew, PhD, Kathleen Dungan, MD, MPH, Bill Evans, BA, Thomas Ewing, PhD, Corinne Fantz, PhD, DABCC, Alexander Fleming, MD, Robert A. Gabbay, MD, PhD, Paul Gerrard, MD, Patricia Gomez, MD, Ronald Goodstein, PhD, Daniel Griffin, MD, PhD, Alberto Gutierrez, PhD, T.S. Harvey, PhD, Shuhan He, MD, Rosalind Hollingsworth, PhD, Korey Hood, PhD, Jeffrey Joseph, DO, Jessie Juusola, PhD, David C. Kaslow, MD, Dave Kleidermacher, BS, Nevan Krogan, PhD, Wei-An (Andy) Lee, DO, Simin Liu, MD, ScD, MPH, MS, Vickie M. Mays, PhD, Ateev Mehrotra, MD, MPH, Jordan Messler, MD, SFHM, FACP, Joshua Miller, MD, MPH, Bobak Mortazavi, PhD, K. M. Venkat Narayan, MD, MSc, MBA, Aaron Neinstein, MD, Christopher McKnight Nichols, PhD, Nancy Nielsen, MD, PhD, Kirsten Nørgaard, MD, DMSc, David O’Neal, MD, FRACP, Darin Olson, MD, PhD, Francisco J. Pasquel, MD, MPH, Yarmela Pavlovic, JD, William Polonsky, PhD, CDCES, Bruce Quinn, MD, PhD, Gerry Rayman, MD, FRCP, Jennifer Raymond, MD, MCR, Eun-Jung Rhee, MD, PhD, Robert Rushakoff, MD, George Rutherford, III, MD, MA, Jonathan Schmitz, MD, PhD, Laurien Sibomana, MS, James Tabery, PhD, Matthew Taylor, CFA, Nam Tran, PhD, Deborah Wake, MBChB, BSc, PhD, Clin Ed Dip, Kayo Waki, MD, MPH, PhD, David Weissman, MD, Elissa Weitzman, ScD, MSc, and Lynn M. Yee, MD, MPH. The author(s) received no financial support for the research, authorship, and/or publication of this article.
Publisher Copyright:
© 2021 Diabetes Technology Society.
PY - 2021
Y1 - 2021
N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has rapidly involved the entire world and exposed the pressing need for collaboration between public health and other stakeholders from the clinical, scientific, regulatory, pharmaceutical, and medical device and technology communities. To discuss how to best protect people with diabetes from serious outcomes from COVID-19, Diabetes Technology Society, in collaboration with Sansum Diabetes Research Institute, hosted the “International COVID-19 and Diabetes Virtual Summit” on August 26-27, 2020. This unique, unprecedented real-time conference brought together physicians, scientists, government officials, regulatory experts, industry representatives, and people with diabetes from six continents to review and analyze relationships between COVID-19 and diabetes. Over 800 attendees logged in. The summit consisted of five sessions: (I) Keynotes, (II) Preparedness, (III) Response, (IV) Recovery, and (V) Surveillance; eight parts: (A) Background, (B) Resilience, (C) Outpatient Care, (D) Inpatient Care, (E) Resources, (F) High-Risk Groups, (G) Regulation, and (H) The Future; and 24 sections: (1) Historic Pandemics and Impact on Society, (2) Pathophysiology/Risk Factors for COVID-19, (3) Social Determinants of COVID-19, (4) Preparing for the Future, (5) Medications and Vaccines, (6) Psychology of Patients and Caregivers, (7) Outpatient Treatment of Diabetes Mellitus and Non-Pharmacologic Intervention, (8) Technology and Telehealth for Diabetes Outpatients, (9) Technology for Inpatients, (10) Management of Diabetes Inpatients with COVID-19, (11) Ethics, (12) Accuracy of Diagnostic Tests, (13) Children, (14) Pregnancy, (15) Economics of Care for COVID-19, (16) Role of Industry, (17) Protection of Healthcare Workers, (18) People with Diabetes, (19) International Responses to COVID-19, (20) Government Policy, (21) Regulation of Tests and Treatments, (22) Digital Health Technology, (23) Big Data Statistics, and 24) Patient Surveillance and Privacy. The two keynote speeches were entitled (1) COVID-19 and Diabetes—Meeting the Challenge and (2) Knowledge Gaps and Research Opportunities for Diabetes and COVID-19. While there was an emphasis on diabetes and its interactions with COVID-19, the panelists also discussed the COVID-19 pandemic in general. The meeting generated many novel ideas for collaboration between experts in medicine, science, government, and industry to develop new technologies and disease treatment paradigms to fight this global pandemic.
AB - The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has rapidly involved the entire world and exposed the pressing need for collaboration between public health and other stakeholders from the clinical, scientific, regulatory, pharmaceutical, and medical device and technology communities. To discuss how to best protect people with diabetes from serious outcomes from COVID-19, Diabetes Technology Society, in collaboration with Sansum Diabetes Research Institute, hosted the “International COVID-19 and Diabetes Virtual Summit” on August 26-27, 2020. This unique, unprecedented real-time conference brought together physicians, scientists, government officials, regulatory experts, industry representatives, and people with diabetes from six continents to review and analyze relationships between COVID-19 and diabetes. Over 800 attendees logged in. The summit consisted of five sessions: (I) Keynotes, (II) Preparedness, (III) Response, (IV) Recovery, and (V) Surveillance; eight parts: (A) Background, (B) Resilience, (C) Outpatient Care, (D) Inpatient Care, (E) Resources, (F) High-Risk Groups, (G) Regulation, and (H) The Future; and 24 sections: (1) Historic Pandemics and Impact on Society, (2) Pathophysiology/Risk Factors for COVID-19, (3) Social Determinants of COVID-19, (4) Preparing for the Future, (5) Medications and Vaccines, (6) Psychology of Patients and Caregivers, (7) Outpatient Treatment of Diabetes Mellitus and Non-Pharmacologic Intervention, (8) Technology and Telehealth for Diabetes Outpatients, (9) Technology for Inpatients, (10) Management of Diabetes Inpatients with COVID-19, (11) Ethics, (12) Accuracy of Diagnostic Tests, (13) Children, (14) Pregnancy, (15) Economics of Care for COVID-19, (16) Role of Industry, (17) Protection of Healthcare Workers, (18) People with Diabetes, (19) International Responses to COVID-19, (20) Government Policy, (21) Regulation of Tests and Treatments, (22) Digital Health Technology, (23) Big Data Statistics, and 24) Patient Surveillance and Privacy. The two keynote speeches were entitled (1) COVID-19 and Diabetes—Meeting the Challenge and (2) Knowledge Gaps and Research Opportunities for Diabetes and COVID-19. While there was an emphasis on diabetes and its interactions with COVID-19, the panelists also discussed the COVID-19 pandemic in general. The meeting generated many novel ideas for collaboration between experts in medicine, science, government, and industry to develop new technologies and disease treatment paradigms to fight this global pandemic.
KW - COVID-19
KW - diabetes
KW - digital health
KW - pandemic
KW - telehealth
UR - http://www.scopus.com/inward/record.url?scp=85099964762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099964762&partnerID=8YFLogxK
U2 - 10.1177/1932296820978399
DO - 10.1177/1932296820978399
M3 - Article
C2 - 33476193
AN - SCOPUS:85099964762
SN - 1932-2968
VL - 15
SP - 478
EP - 514
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
IS - 2
ER -
